The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | Unmet needs in the current therapeutic landscape for squamous cell anal carcinoma
Stefano Kim, MD, Centre Hospitalier Universitaire de Besançon, Besançon, France, discusses unmet needs in stage three hepatocellular carcinoma (HCC), where there is a high recurrence rate of around 40%. Traditionally, patients with stage three disease were treated similarly to those with smaller lesions due to the lack of effective systemic treatments. The ongoing Phase II study INTERACT-ION (NCT04719988) trial represents a shift in the treatment paradigm for these patients, addressing the gap in available therapies. In advanced trials, there is ongoing evaluation of combinations involving chemotherapy and immunotherapy, as well as tumor vaccines. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
